By Dominic Chopping 
 

Novo Nordisk A/S (NVO) is to discontinue its activities within inflammatory disorders after deciding to increase efforts within diabetes prevention and treatment, obesity and diabetes complications, it said Tuesday.

It said 400 jobs will be directly impacted, but it expects to offer over half of them new positions within the company.

The decision follows a strategic review and comes after the company recently announced the discontinuation of its rheumatoid arthritis treatment anti-IL-20.

Chief science officer Mads Krogsgaard Thomsen said "the discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s...we have therefore decided to further increase our R&D efforts within diabetes which is our main business area."

The company expects to book a DKK700 million charge from impairments and other exit costs.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novo Nordisk Charts.